What type of study is this?

This is a Experimental Study study.

September 24, 2025Open Access

Inhibition of 3-mercaptopyruvate sulfurtransferase enhances CD8⁺ T-cell antitumor immunity

View Full Paper

Ask AI

Bookmark

Authors

Pharmacological inhibition of 3-MST improved CD8+ T-cell activation in renal cell carcinoma, suggesting a potential for immunotherapy.

Inhibiting 3-MST improves CD8+ T-cell immune responses against renal cell carcinoma (RCC), enhancing tumor cell killing.
High expression of 3-MST in RCC correlates with poorer patient survival and reduces standard immune responses.
Pharmacological inhibition of 3-MST decreased intracellular hydrogen sulfide levels, leading to increased apoptosis and enhanced immunogenic marker expression.
Partial 3-MST inhibition promotes T-cell activation, indicating its role as a metabolic driver of tumor growth and immune evasion.

Urwyler et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark